Hypertension treatment drugs may play a role in boosting clinical immunotherapy
8 June 2023
Team from the Van den Eynde group have discovered that some molecules previously used to treat hypertension might also help the immune system to better fight cancer cells
Oxford DeLIVER research attracts 1000 patients for innovative Pearl clinical study
30 May 2023
1000 patients have been recruited for the Pearl study within the DeLIVER programme.
Ludwig Oxford scientists participate in symposia for aspiring your scientists
19 May 2023
As part of the Scientists in Schools programme, Dr Carol Leung and Oliver Featherstone give talks to students on their work in cancer research.
Ludwig Oxford's Professor Yang Shi elected to Academy of Medical Sciences
18 May 2023
Ludwig Oxford's Yang Shi has been announced as a Fellow of the Academy of Medical Sciences
Ludwig Oxford Principal Investigators host interns for NDM’s summer studentships
2 May 2023
Three research teams within Ludwig Institute for Cancer Research Oxford are looking to host undergraduate and Masters students as an exciting opportunity to experience active research in an Oxford University Institute.
CAPS+ method provides improved detection of cytosine modifications in double-stranded DNA
4 April 2023
Ludwig Oxford’s Professor Chunxiao Song develops a new method, CAPS+, for improved detection of modifications to the DNA base cytosine
Lithuanian Ambassador visits Ludwig Oxford’s Skirmantas Kriaucionis
15 February 2023
The Lithuanian Ambassador to the United Kingdom, His Excellency Mr. Eitvydas Bajarūnas, paid visit to Professor Skirmantas Kriaucionis last week at Ludwig Oxford
iASPP as a regulator of immunological tolerance
6 February 2023
Researchers from the Lu lab identify iASPP to be a key component in the anti-tumour immune response
HIF and AHR transcription factors interact in kidney carcinomas raising the potential for effective combination therapy
6 February 2023
Ludwig Oxford’s David Mole and Peter Ratcliffe show interaction between transcription factors HIF and AHR, indicating a combined approach to therapy may provide greater efficacy for cancer treatment.
Ludwig’s Tammie Bishop awarded Associate Professorship
10 January 2023
Congratulations to Tammie Bishop, who is made associate professor at the University of Oxford.
Pan-cancer gene signature provides insights into HIF pathway activation
29 November 2022
Researchers from David Mole’s and Peter Ratcliffe’s laboratories establish a HIF metagene for studying hypoxia pathways.
Professor Xin Lu featured in Ludwig's Women in Science report
24 November 2022
Ludwig Oxford’s Professor Xin Lu recounts her experiences in Ludwig Cancer Research’s special Women in Science report.
Ludwig Oxford’s Dr Parinaz Mehdipour celebrates local young scientists
23 November 2022
Parinaz shared insights into her career during the Science Oxford event recognising outstanding Year 13 STEM students in Oxfordshire and Buckinghamshire
Ludwig Oxford student awarded NDM graduate student prize
18 November 2022
Dr Tom Carroll from the Lu lab receives a Highly Commended award under the NDM overall graduate student prize
Ludwig Oxford research wins Journal for ImmunoTherapy of Cancer’s best basic tumour immunology paper of 2022
15 November 2022
A paper on a therapeutic cancer vaccine from the Van den Eynde lab was singled out for this award celebrating excellence in scientific research.
Algebraic, geometric, and topological data analysis methods enhance systems biology model of ERK kinetics.
3 November 2022
A mathematical analysis carried out by the Byrne group and colleagues brings new understanding to a recently published kinetic model of ERK phosphorylation.
Mechanistic insights into the ZBP1 inflammatory response
21 October 2022
A collaborative study, led by former Ludwig Oxford group leader Professor Mads Gyrd-Hansen, sheds light on the ZBP1-induced signalling pathway, a pathway which contributes to the viral immune response, including to SARS-CoV-2
Unexpected role of iASPP as a tumour suppressor
18 October 2022
The Lu lab reveals that the previously characterised oncogene, iASPP, acts as a tumour suppressor in mutant RAS- and inflammation-driven skin cancers.
Two new therapeutic targets in tuft cell-like small cell lung cancer
18 October 2022
Yang Shi’s group identify two transcriptional co-activators that are selectively important for cancer cell but not normal cell survival.
Ludwig Oxford's Yang Shi elected to National Academy of Medicine
17 October 2022
Ludwig Cancer Research congratulates Yang Shi on one of the highest honours in the fields of health and medicine